RECKing MMP function: implications for cancer development
Abstract
Cancer is a multistage process requiring progressive genetic and epigenetic changes in neoplastic and responding stromal cells. Many alterations that occur during the process of malignant progression are regulated by the matrix metalloproteinase (MMP) family of extracellular proteases and their endogenous inhibitors. Recent work has identified a new cell-surface inhibitor of MMPs - RECK. RECK regulates MMP-induced pericellular signaling cascades during embryogenesis and tumorigenesis. Homozygous loss of RECK results in embryonic lethality and attenuated tumor development in adults - thus providing further support for an efficacious role for protease inhibitors as anticancer therapeutics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RECK is a GPI-anchored protein that binds and inhibits metalloproteases including ADAM10.
“RECK is a GPI-anchored protein that binds and inhibits metalloproteases that include ADAM10 (18–21).”
From GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein (2021) · cites this paper as [19]
Cited by
Sorted by citations
GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein
Nakamura, M., Li, Y., Choi, B.-R., Matas-Rico, E., Troncoso, J., Takahashi, C., & Sockanathan, S. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6178 · Cited by 38 · see citing works
- Authors
- Rhee, J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Rhee, J
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2002-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 209-211
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W2068498906
- Cited by
- 118
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 7 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- RECK, matrix metalloproteinases, matrix metalloproteinase inhibitors, extracellular protease, tumor stroma, malignant progression, tumor microenvironment, protease inhibitors, anticancer agents, embryonic lethality
- MeSH terms
- Animals, Catalysis, Humans, Membrane Glycoproteins, Models, Biological, Neoplasms, Signal Transduction, Gene Expression Regulation, Enzymologic, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Matrix Metalloproteinases, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
